President and CEO Clay Siegall cofounded the biotechnology company Seattle Genetics in 1998. The company has a massive pipeline of multiple antibody drugs aimed to aid in the treatment of cancer. They are well known for the successful cancer drug ADCETRIS (brentuximab vedotin). They have secured $675 million through public and private funding, including the initial public offering in 2011. However, the company is not yet profitable. According to Siegall, their first concern is to expand and worry about profits later on; this is not unusual for pharmaceutical companies. In 2015 they began to expand their business both in facilities and in employees. By 2020, they hope to have hired a total of 1300 more employees.
The President and CEO, Clay Siegall, has an extensive list of accomplishments throughout his career as a scientist. He earned a B.S. in Zoology from the University of Maryland and a Ph.D. in Genetics from The George Washington Universtiy. From 1988 to 1991, Siegall worked at the National Cancer Institue, Institutes of Health, and then moved on to work for Bristol-Myers Squibb Pharmaceutical Research Institue from 1991 to 1997. He then cofounded Seattle Genetics in 1998.
On top of being the President and CEO of Seattle Genetics, Clay Siegall is also the Director of Ultragenyx Pharmaceutical, the Director of MirnaTherapecetics, INC (Nasdaq: ALDR), and the Director of Alder Biopharmaceuticals Inc. He’s also written more than 70 publications and has acquired 15 patents.
Contributing to his accomplishments, Mr. Siegall was awarded the Alumnus of the Year award for Computer, Math, and Natural Sciences from the University of Maryland in 2013, and was named Entrepreneur of the Year by Pacific Northwest Ernst and Young in 2012.
Clay Siegall and Seattle Genetics have a rewarding history and hold a prosperous future in the pharmaceutical business.